This study is currently recruiting.
Description: This research study titled, Epidiolex® For the Treatment Of Anxiety Comorbidity In Refractory Pediatric Epilepsy (EAPE), is being conducted by Dr. Jay Salpekar to evaluate if the drug FDA approved drug, Epidiolex®, helps control anxiety and mood symptoms associated with recurrent seizures in addition to seizure control. The length of the study is 4 months and consists of 11 visits; some are remote and some are onsite.
If you or a family member have any questions or are interested in learning more about the study please contact the study staff by replying to this notice or by contacting the staff directly with the information below.
Eligibility & Criteria
IRB #: IRB00282248
Principal Investigator: Dr. Jay Salpekar
Eligible Age Range: 6-17 years
Gender: All
Diagnosis: Anxiety, Anxiety Disorder, Epilepsy, Seizures